SCHEMBL3636095

SCHEMBL3636095

CNCc1cc2ccc(C)cc2cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.45
CYP1A2 P05177 3/20 0.45
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 2/20 0.42
TDP1 Q9NUW8 1/20 0.39
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A2 P23975 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PI4KA P42356 1/20 0.36
PIK3CG P48736 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
CD274 Q9NZQ7 1/20 0.35
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3641019 0.93 CYP2A6 (0.43) CYP2A6CYP1A2ALDH1A1KDM4EHSD17B10
SCHEMBL3637748 0.81 L3MBTL1 (0.43) CYP2A6CYP1A2SLC6A4SLC6A2PIK3CD
SCHEMBL3642128 0.81 KDM4E (0.43) CYP2A6KDM4ESLC6A4SLC6A2TP53
SCHEMBL3633864 0.80 ATM (0.51) CYP2A6CYP1A2KDM4ESLC6A4SLC6A2
SCHEMBL3636113 0.75 CASP3 (0.43) SLC6A4PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL3641870 0.75 KDM4E (0.43) KDM4ESLC6A4SLC6A2PIK3CDPIK3CA
SCHEMBL14540066 0.74 CCR1 (0.44) KDM4ECCR1CCR5CCR8SLC6A4
SCHEMBL12963786 0.73 CYP1A2 (0.48) CYP2A6CYP1A2ALDH1A1TDP1CCR1
SCHEMBL26934895 0.73 CYP2A6 (0.50) CYP2A6CYP1A2TDP1CCR1CCR5
SCHEMBL27015033 0.72 CYP2A6 (0.54) CYP2A6CYP1A2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155751-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2010-02-24 EP disclosed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 US disclosed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 CYP2A6 359/4885CYP1A2 258/4885ALDH1A1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.